[CIMB] QoQ Annualized Quarter Result on 31-Dec-2023 [#4]

Announcement Date
29-Feb-2024
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2023
Quarter
31-Dec-2023 [#4]
Profit Trend
QoQ- -0.57%
YoY- 28.33%
View:
Show?
Annualized Quarter Result
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
Revenue 22,462,998 22,515,836 21,014,482 20,852,338 20,662,396 19,988,980 19,837,516 8.64%
PBT 10,605,928 10,293,240 9,540,731 9,613,353 9,435,804 8,945,556 8,371,010 17.10%
Tax -2,621,644 -2,359,532 -2,378,636 -2,411,126 -2,414,814 -2,186,976 -2,778,079 -3.79%
NP 7,984,284 7,933,708 7,162,095 7,202,226 7,020,990 6,758,580 5,592,931 26.81%
-
NP to SH 7,794,618 7,745,408 6,980,962 7,021,053 6,835,996 6,579,640 5,439,863 27.12%
-
Tax Rate 24.72% 22.92% 24.93% 25.08% 25.59% 24.45% 33.19% -
Total Cost 14,478,714 14,582,128 13,852,387 13,650,112 13,641,406 13,230,400 14,244,585 1.09%
-
Net Worth 68,888,971 67,615,680 68,327,042 68,203,327 66,992,836 65,326,948 62,114,290 7.15%
Dividend
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
Div 5,768,343 - 4,585,993 2,488,523 3,732,785 - 2,756,206 63.68%
Div Payout % 74.00% - 65.69% 35.44% 54.60% - 50.67% -
Equity
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
Net Worth 68,888,971 67,615,680 68,327,042 68,203,327 66,992,836 65,326,948 62,114,290 7.15%
NOSH 10,694,028 10,665,106 10,665,106 10,665,106 10,665,106 10,665,106 10,665,106 0.18%
Ratio Analysis
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
NP Margin 35.54% 35.24% 34.08% 34.54% 33.98% 33.81% 28.19% -
ROE 11.31% 11.46% 10.22% 10.29% 10.20% 10.07% 8.76% -
Per Share
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
RPS 210.29 211.12 197.04 195.52 193.74 187.42 187.13 8.09%
EPS 73.02 72.64 65.46 65.83 64.10 61.68 52.18 25.13%
DPS 54.00 0.00 43.00 23.33 35.00 0.00 26.00 62.85%
NAPS 6.449 6.3399 6.4066 6.395 6.2815 6.1253 5.8594 6.60%
Adjusted Per Share Value based on latest NOSH - 10,665,106
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
RPS 209.55 210.05 196.04 194.53 192.76 186.47 185.06 8.64%
EPS 72.71 72.26 65.12 65.50 63.77 61.38 50.75 27.11%
DPS 53.81 0.00 42.78 23.22 34.82 0.00 25.71 63.69%
NAPS 6.4265 6.3077 6.3741 6.3626 6.2496 6.0942 5.7945 7.15%
Price Multiplier on Financial Quarter End Date
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
Date 28/06/24 29/03/24 29/12/23 29/09/23 30/06/23 31/03/23 30/12/22 -
Price 6.80 6.64 5.85 5.43 5.06 5.31 5.80 -
P/RPS 3.23 3.15 2.97 2.78 2.61 2.83 3.10 2.77%
P/EPS 9.32 9.14 8.94 8.25 7.89 8.61 11.30 -12.06%
EY 10.73 10.94 11.19 12.12 12.67 11.62 8.85 13.71%
DY 7.94 0.00 7.35 4.30 6.92 0.00 4.48 46.50%
P/NAPS 1.05 1.05 0.91 0.85 0.81 0.87 0.99 4.00%
Price Multiplier on Announcement Date
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
Date 30/08/24 31/05/24 29/02/24 30/11/23 30/08/23 31/05/23 28/02/23 -
Price 8.20 6.84 6.46 5.65 5.63 4.82 5.61 -
P/RPS 3.90 3.24 3.28 2.89 2.91 2.57 3.00 19.13%
P/EPS 11.24 9.42 9.87 8.58 8.78 7.81 10.93 1.88%
EY 8.90 10.62 10.13 11.65 11.38 12.80 9.15 -1.83%
DY 6.59 0.00 6.66 4.13 6.22 0.00 4.63 26.55%
P/NAPS 1.27 1.08 1.01 0.88 0.90 0.79 0.96 20.53%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment